{"type":"rich","version":"1.0","title":"The BioPharm Brief: Capital, Antibodies, and Algorithms","description":"Today’s BioPharm Brief looks at new financing for multispecific antibody development, AbCellera’s $200 million public offering, and an expanded AI collaboration between Nucleai and Gilead focused on ADC development.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43785890/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}